Sunitinib Malate With Hormonal Ablation for Patients Who Will Have Prostatectomy
Status:
Active, not recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to learn if the addition of sunitinib malate
(SU011248) to hormone based castration is an effective treatment for shrinking or controlling
the tumor before having the prostate removed.